Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Glipizide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC8 known ✓ | Q09428 | 2/20 | 0.59 |
| ▸ | KCNJ11 known ✓ | Q14654 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PPARG | P37231 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glipizide SCHEMBL1536893 | 1.00 | TSHR (1.00) | TSHRLMNABLMCYP2C9CYP3A4 | |
| Glipizide SCHEMBL29366401 | 1.00 | TSHR (1.00) | TSHRLMNABLMCYP2C9CYP3A4 | |
| Glipizide SCHEMBL2057153 | 0.99 | TSHR (0.98) | TSHRLMNABLMCYP2C9CYP3A4 | |
| Glipizide SCHEMBL28867262 | 0.99 | TSHR (0.98) | TSHRLMNABLMCYP2C9CYP3A4 | |
| Glipizide SCHEMBL27573879 | 0.99 | TSHR (0.98) | TSHRLMNABLMCYP2C9CYP3A4 | |
| Glipizide SCHEMBL27728874 | 0.99 | TSHR (0.98) | TSHRLMNABLMCYP2C9CYP3A4 | |
| Glipizide SCHEMBL2324977 | 0.95 | TSHR (0.90) | TSHRLMNABLMCYP2C9CYP3A4 | |
| Glipizide SCHEMBL7716609 | 0.95 | LMNA (0.90) | TSHRLMNABLMCYP2C9CYP3A4 | |
| Glipizide SCHEMBL13427376 | 0.94 | LMNA (0.90) | TSHRLMNABLMCYP2C9CYP3A4 | |
| SCHEMBL30519378 | 0.92 | CYP2C9 (0.84) | TSHRLMNABLMCYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 46202 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124282-A1 | DECORIN FOR ITS USE IN THE TREATMENT OF DIABETES | CENTRE EUROPEEN D'ETUDE DU DIABETE (FR) | 2026-05-07 | — | — | US | claimed |
| EP-4731239-A1 | ANALOGUES WITH IMPROVED PROPERTIES | Zealand Pharma A/S (DK) | 2026-04-29 | — | — | EP | claimed |
| US-12599564-B2 | Antidiabetic pharmaceutical compositions | Elite Pharmaceutical Solution Inc. (US) | 2026-04-14 | — | — | US | claimed |
| EP-4717267-A1 | SYNERGISTIC COMBINATION FOR TREATING CANCER | FUNDACION UNIVERSITARIA SAN ANTONIO (UCAM) (ES) | 2026-04-01 | — | — | EP | claimed |
| US-20260069550-A1 | TRANSDERMAL DELIVERY OF ANTIDIABETIC AGENTS | RITTENHOUSE CHRISTINE (US) | 2026-03-12 | — | — | US | claimed |
| EP-3608338-B1 | HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR | REGENERON PHARMA (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4705280-A1 | DIARYL UREA-BASED COMPOUNDS AND RELATED COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DIABETES MELLITUS AND NEURODEGENERATIVE DISEASE | Purdue Research Foundation (US) | 2026-03-11 | — | — | EP | claimed |
| CN-223950626-U | Glipizide tablet medicament hopper promotes feeder | 华裕(无锡)制药有限公司 | 2026-02-27 | — | — | CN | claimed |
| EP-4684799-A2 | ANTIBODIES THAT DISRUPT THE INTERACTION OF GAL3 AND INSULIN RECEPTOR OR INTEGRINS AND METHODS OF USE THEREOF | TrueBinding, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| US-12527754-B2 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | TUFTS MEDICAL CENTER, INC. (US) | 2026-01-20 | — | — | US | claimed |
| US-4792448-A | Generic zero order controlled drug delivery system | PFIZER INC. (US) | 1988-12-20 | — | — | US | claimed |
| EP-0294993-A1 | A generic zero order controlled drug delivery system | PFIZER INC. (US) | 1988-12-14 | — | — | EP | claimed |
| EP-0271983-A1 | Transdermal flux enhancing compositions | PFIZER INC. (US) | 1988-06-22 | — | — | EP | claimed |
| CN-87107548-A | Strengthen the compositions of transdermal flux | — | 1988-05-11 | — | — | CN | claimed |
| EP-0259113-A2 | Controlled release device for an active substance | PFIZER INC. (US) | 1988-03-09 | — | — | EP | claimed |
| US-4708868-A | Oral anti-diabetic pharmaceutical forms and the preparation thereof | DR. KARL THOMAE GMBH (DE) | 1987-11-24 | — | — | US | claimed |
| US-4696815-A | Anti-diabetic pharmaceutical forms and the preparation thereof | DR. KARL THOMAE GMBH (DE) | 1987-09-29 | — | — | US | claimed |
| EP-0091193-B1 | ANTIDIABETIC COMPOSITIONS | PFIZER INC. (US) | 1986-05-21 | — | — | EP | claimed |
| EP-0149592-A2 | Process for the preparation of a pharmacologically active sulphonylurea derivative | LÄKEMEDELSFABRIKEN-MEDICA AB (FI) | 1985-07-24 | — | — | EP | claimed |
| EP-0091193-A2 | Antidiabetic compositions | PFIZER INC. (US) | 1983-10-12 | — | — | EP | claimed |